arrow
Ying Yuan 封面图

Ying Yuan

zhejiang university school of medicineAssociate Professor (tenured), Department of Biostatistics邮箱:yuanying1999@zju.edu.cn
H指数:54
被引数:1.2万

个人简介

As a statistical expert in biomedical research, the scholar’s primary focus is on developing innovative designs, methods, and tools for data analysis, with particular interest in Bayesian adaptive clinical trial design, statistical analysis of longitudinal data and missing data, and mediation analysis. Currently serving as the contact Principal Investigator for the Coordination and Data Management Center (CDMC) for the Consortium for the Study of Chronic Pancreatitis, Diabetes and Pancreatic Cancer (U01) and for the Translational and Basic Science Research in Early Lesions (U24), the scholar also serves as the Biostatistics and Bioinformatics Core Director for several Specialized Programs of Research Excellence (SPORE), including the Ovarian Cancer (P50CA217685), Brain Cancer (P50CA127001), and Gastrointestinal Cancer (P50CA221707). The scholar is the Chair of the institutional Data and Safety Monitoring Board (DSMB) at The University of Texas MD Anderson Cancer Center, overseeing over 100 ongoing randomized clinical trials.

教育背景

  • 2005.12

    University of Michigan, Ann Arbor, Michigan, US Ph.D Biostatistics

  • 2000.12

    Brandeis University, Waltham, Massachusetts, US M.S Biochemistry

  • 1998.12

    Peking University, Beijing, CN M.S Biochemistry

  • 1995.12

    Huazhong University of Science and Technology, Wuhan, CN BS Biomedical Engineering

工作经历

  • 2010.01 – 2016.12

    The University of Texas MD Anderson Cancer Center, Houston, TX

    Associate Professor (tenured), Department of Biostatistics

  • 2005.01 – 2010.12

    The University of Texas MD Anderson Cancer Center, Houston, TX

    Assistant Professor, Department of Biostatistics

  • 2001.01 – 2005.12

    University of Michigan, Ann Arbor, MI

    Graduate Research Assistant

  • 2001.01 – 2003.12

    University of Michigan, Ann Arbor, MI

    Summer Statistical Consultant

荣誉奖项

  1. Elected Fellow, American Statistical Association(2017)
  2. Elected Fellow, International Statistical Institute(2015)
  3. Rackham Travel Grant Award(2004)|University of Michigan
  4. Outstanding Performance First Year MS Program(2001)|University of Michigan
  5. Brandeis Graduate Fellowship(1998)|University of Brandeis
Oral KRAS G12D inhibitor GFH375 for previously treated advanced solid tumors with KRASG12D mutations: a phase 1 trial

口服KRAS G12D抑制剂GFH375用于既往治疗过的KRASG12D突变晚期实体瘤:一项1期临床试验

2026-09-150
PRE
First-line anlotinib versus bevacizumab plus CapeOX in RAS/BRAF wild-type unresectable metastatic colorectal cancer (ANCHOR): a multicenter, prospective, randomized, phase 3 trial

ANCHOR研究:一线安罗替尼与贝伐珠单抗联合卡培他滨/奥沙利铂治疗RAS/BRAF野生型不可切除转移性结直肠癌的多中心、前瞻性、随机、III期临床试验

2026-09-010
OA
CERN 09-02: A PHASE 2 TRIAL OF CARBOPLATIN AND BEVACIZUMAB FOR RECURRENT ADULT EPENDYMOMA

CERN 09-02:一项关于卡铂和贝伐珠单抗治疗复发性成人室管膜瘤的II期临床试验

2025-11-010
OAAI
A multicenter randomized phase II trial of lenvatinib plus everolimus versus cabozantinib in patients with metastatic clear cell RCC that progressed on PD-1 immune checkpoint inhibition (LenCabo)

一项多中心随机II期试验,比较仑伐替尼联合依维莫司与卡博替尼在PD-1免疫检查点抑制剂进展后的转移性透明细胞肾细胞癌患者中的疗效(LenCabo)。

2025-10-180
PRE
Serial multiomics uncovers anti-glioblastoma responses not evident by routine clinical analyses

串行多组学揭示了常规临床分析中未能显现的抗胶质母细胞瘤反应

2025-10-080
PRE